Choose a language and wait for the translated text.
Shots:
Pharming Group has launched Joenja in Japan for activated PI3K delta syndrome (APDS) patients aged 4 years and older following NHI reimbursement listing
As per the agreement with Pharming, OrphanPacific serves as Joenjaโs Marketing Authorization Holder in Japan &, alongside Pharming, manages the productโs supply & distribution
Leniolisib is under regulatory review for pediatric APDS in several countries and is also being evaluated in two P-II trials for primary immunodeficiencies with immune dysregulation
Ref: Pharming Group | Image: Pharming Group | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
The post Pharming Group Launches Joenja in Japan for APDS appeared first on PharmaShots.
